Alzheimer's disease drugs discovery services

Alzheimer's disease cellular model for drugs discovery services

Beta-Amyloid peptide-induced toxicity in primary cultures of neurons is a well established and reliable experimental model of Alzheimer's disease. Fluofarma offers drug discovery services using its Alzheimer’s disease cellular model for the identification of neuroprotective drugs.

Fluofarma developed several additional innovative tools for Alzheimer’s disease drug discovery services:

• Cellular models: Human engineered cell lines and primary cultures of neurons grown in 96-well plates
• Neurodegeneration models: Cellular models that mimic Alzheimer’s disease
• Molecular reporter: Human cell lines expressing proprietary recombinant biosensors measuring key steps of neurodegeneration

Fluofarma offers comprehensive drug discovery services:

• Large-scale screening of in cell line or in primary cultures of neurons
• Selection and prioritization lead compounds using our predictive Alzheimer’s disease model
• Determination of the mechanism of action

For more information on our Alzheimer's disease drugs discovery services

If you need to have further details on our Alzheimer's disease drugs discovery services, do not hesitate to contact us.